

Title: Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients

Header: COVID-19 causes olfactory but no gustatory loss

Keywords: Olfaction disorder, Taste disorder, Smell, Taste

Constantin A. Hintschich, Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

Jürgen J. Wenzel, M.D., Institute of Clinical Microbiology and Hygiene, Regensburg University Hospital, Regensburg, Germany

Thomas Hummel, M.D., Smell & Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany

Mohammed K. Hankir, PhD, Department of Experimental Surgery, Würzburg University Hospital, Würzburg, Germany

Thomas Kühnel, M.D., Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

Veronika Vielsmeier*, M.D., Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/alr.22655](#).

This article is protected by copyright. All rights reserved.

Hintschich

Christopher Bohr*, M.D., Department of Otorhinolaryngology, Regensburg University Hospital,
Regensburg, Germany

* Authors contributed equally

Corresponding author:

Constantin A. Hintschich

Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

Franz-Josef-Strauss-Allee 11

93053 Regensburg

Germany

email: constantin.hintschich@klinik.uni-regensburg.de

phone: +49 941 944 9401

fax: +49 941 944 9402

Declaration of disclosures:

Thomas Hummel reported receiving research funding from Sony, The Smell and Taste Lab, Takasago, and aspUraclip. Constantin A. Hintschich, Jürgen J. Wenzel, Mohammed Hankir, Thomas Kühnel, Veronika Vielsmeier and Christopher Bohr declare no disclosures.

Hintschich

To the Editor,

The current COVID-19 pandemic is challenging healthcare systems and societies worldwide in an unprecedented way. Unspecific symptoms including fever and cough are frequently observed and serve as indicators for home quarantine and molecular testing by PCR¹. Interestingly, sudden dysfunctions in smell and taste have been described, first anecdotally, and then in retrospective reports^{2, 3}. These pathognomonic symptoms have led to the consensus that olfactory and gustatory defects should equally be regarded as highly suspicious for SARS-CoV-2 infection, even in the absence of other symptoms⁴. Due to home quarantine and the short duration of chemosensitive disorders, reports so far have mostly been retrospective. Psychophysical tests of olfactory and gustatory function have mainly been performed in hospitalized patients only⁵.

Here, we report on a controlled prospective trial enrolling COVID-19 patients from southeast Germany to objectively assess complaints of smell and taste loss using reliable and validated psychophysical tests. Respiratory samples of all subjects were tested positive for the presence of SARS-CoV-2 RNA by RT-qPCR in the diagnostic unit of our tertiary care hospital. Patients under home quarantine were contacted directly after a positive result had been reported. Following informed consent, participants were sent both a 4-item smell test ("Pocket Smell Test"; Sensonics, USA) and a 4-item taste test ("Taste Strips"; taste qualities of sweet, sour, salty, and bitter; Burghart Messtechnik, Germany). A combined online manual and questionnaire ensured correct self-administration and queried subjective smell and taste. In the case of a suspected pregnancy, the bitter strip was skipped to prevent possible adverse effects through quinine hydrochloride. Hyposmia and hypogeusia respectively were defined as ≥ 1 incorrect answer. Statistical analysis was done by Fisher's exact test (SPSS, version 26.0, SPSS, USA). $p < 0.05$ was regarded as significant.

A total of 41 (median age 37 years, 68% female, 32% male) patients answered the online questionnaire and self-administered the olfactory and gustatory tests in median 5 days after the positive SARS-CoV-2 PCR result and 13 days after the first symptoms. As shown in Table 1, 25 (61%) and 18 (44%) patients described a current hyposmia and hypogeusia, respectively. This is in line with previous reports⁶. There was no case of isolated hypogeusia whereas 28% of patients reported isolated hyposmia. The control group consisted of 30 patients (median age 33 years, 73% female, 27% male) who tested negative for IgG antibodies against SARS-CoV-2. In comparison, the subjective loss in smell and taste occurred significantly more often in COVID-19 patients (61% vs. 10%, $p<0.0001$; 44% vs. 10%, $p=0.0003$; see Table 1). SARS-CoV-2 infection was significantly associated with a positive test for hyposmia but not hypogeusia (54% vs. 27%, $p=0.03$; 20% vs. 10%, $p=0.34$; see Table 1). In COVID-19 patients, the subjective loss in smell was confirmed by a hyposmic test result in 72% whereas the subjective loss in taste was confirmed by a hypogeusic test in only 33%. Within the group of SARS-CoV-2 positive patients, there was a tight dependence between subjective ratings of smell dysfunction and hyposmia in the olfactory test (44%, $p=0.005$; see Table 2). This was not the case for subjective ratings of taste function and gustatory testing (15%, $p=0.11$; see Table 2).

In conclusion, these results demonstrate that a high proportion of COVID-19 patients describe a loss of taste. However, in contrast with prior publications, standardized functional testing of the gustatory modalities of sweet, sour, salty and, bitter did not reveal a bona fide hypogeusia. The subjectively altered taste is most likely caused by impaired retronasal olfaction⁴. To the best of our knowledge, this controlled prospective trial shows for the first time that COVID-19 is tightly associated with olfactory loss but not with gustatory dysfunction when tested psychophysically. Our results may be limited by the relatively small number of study participants. Nevertheless, Moein et al recently demonstrated that

Hintschich

98% of 60 hospitalized COVID-19 patients were hyposmic⁵. It is therefore possible that hyposmia directly relates to SARS-CoV-2 infection severity. Further research is needed to confirm these findings in a larger cohort of COVID-19 patients and to better understand how SARS-CoV-2 impacts the olfactory pathway.

Constantin A. Hintschich, Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

Jürgen J. Wenzel, M.D., Institute of Clinical Microbiology and Hygiene, Regensburg University Hospital, Regensburg, Germany

Thomas Hummel, M.D., Smell & Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany

Mohammed K. Hankir, PhD, Department of Experimental Surgery, Würzburg University Hospital, Würzburg, Germany

Thomas Kühnel, M.D., Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

Veronika Vielsmeier, M.D., Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

Christopher Bohr, M.D., Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

References:

¹ Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5

² Yan, CH, Faraji, F, Prajapati, DP, Boone, CE, DeConde, AS. Association of chemosensory dysfunction and COVID- 19 in patients presenting with influenza- like symptoms. *Int Forum Allergy Rhinol.* Epub 12 April 2020. doi:10.1002/alr.22579

³ Hopkins C, Surda P, Kumar N. Presentation of new onset anosmia during the COVID-19 pandemic. *Rhinology.* 2020 April. doi:10.4193/rhin20.116

⁴ Whitcroft, KL, Hummel, T. Olfactory Dysfunction in COVID-19: Diagnosis and Management. *JAMA.* Epub 20 May 2020. doi:10.1001/jama.2020.8391

⁵ Moein, ST, Hashemian, SM, Mansourafshar, B et al. (2020), Smell dysfunction: a biomarker for COVID- 19. *Int Forum Allergy Rhinol.* Epub 17 April 2020. doi:10.1002/alr.22587

⁶ Tong, JY, Wong, A, Zhu, D, et al. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. *Otolaryngol. Head Neck Surg.* Epub 5 Mai 2020. doi:10.1177/0194599820926473

		SARS-CoV-2 PCR positive	SARS-CoV-2 IgG antibodies negative	p-value
self-reported olfactory function	decreased	25 (61%)	3 (10%)	<0.0001
	normal	16 (39%)	27 (90%)	
self-reported gustatory function	decreased	18 (44%)	3 (10%)	0.003
	normal	23 (56%)	27 (90%)	
smell test	hyposmia	22 (54%)	8 (27%)	0.03
	normosmia	19 (46%)	22 (73%)	
taste test	hypogeusia	8 (20%)	3 (10%)	0.34
	normogeusia	33 (80%)	27 (90%)	

Table 1: self-reported chemosensitive function / results of psychophysical tests vs. SARS-CoV-2 positive / negative; data show are absolute values and relative values as column percentages, respectively.

		SARS-CoV-2 PCR positive		SARS-CoV-2 IgG antibodies negative	
self-reported olfactory function		decreased	normal	decreased	normal
smell test	hyposmia	18 (72%)	4 (25%)	2 (67%)	6 (22%)
	normosmia	7 (28%)	12 (75%) a	1 (33%)	21 (78%)
self-reported gustatory function		decreased	normal	decreased	normal
taste test	hypogeusia	6 (33%)	2 (9%)	2 (67%)	1 (4%)
	normogeusia	12 (67%)	21 (91%) b	1 (33%)	26 (96%)

Table 2: self-reported chemosensitive function vs. results of psychophysical tests; data show are absolute values and relative values as column percentages, respectively; a: $p=0.005$; b: $p=0.11$.